A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
Stephen A. Harrison, Mustafa R. Bashir, Kyoung-Jin Lee, Jennifer Shim-Lopez, Jonathan Lee, Brandee Wagner, Nicholas D. Smith, Hubert C. Chen, Eric Lawitz
Topics & Concepts
TolerabilitySteatohepatitisPlaceboFarnesoid X receptorAgonistInternal medicineMedicineEndocrinologyBile acidGastroenterologyPharmacologyFatty liverReceptorChemistryAdverse effectBiochemistryNuclear receptorPathologyDiseaseAlternative medicineTranscription factorGeneLiver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDrug Transport and Resistance Mechanisms